The NHLBI “Grand Opportunity” Exome Sequencing Project (GO-ESP), a signature project of the NHLBI Recovery Act investment, was designed to identify genetic variants in coding regions (exons) of the human genome (the “exome”) that are associated with heart, lung and blood diseases. These and related diseases that are of high impact to public health and individuals from diverse racial and ethnic groups will be studied. These data may help researchers understand the causes of disease, contributing to better ways to prevent, diagnose, and treat diseases, as well as determine whether to tailor prevention and treatments to specific populations. This could lead to more effective treatments and reduce the likelihood of side effects.
GO-ESP is comprised of five collaborative components:
HeartGO: data and specimens from a consortium of six NHLBI population study cohorts -- ARIC (Atherosclerosis Risk in Communities), CARDIA (Coronary Artery Risk Development in Young Adults), CHS (Cardiovascular Health Study), FHS (Framingham Heart Study), JHS (Jackson Heart Study), and MESA (Multi-Ethnic Study of Atherosclerosis). More...
The NHLBI “Grand Opportunity” Exome Sequencing Project (GO-ESP), a signature project of the NHLBI Recovery Act investment, was designed to identify genetic variants in coding regions (exons) of the human genome (the “exome”) that are associated with heart, lung and blood diseases. These and related diseases that are of high impact to public health and individuals from diverse racial and ethnic groups will be studied. These data may help researchers understand the causes of disease, contributing to better ways to prevent, diagnose, and treat diseases, as well as determine whether to tailor prevention and treatments to specific populations. This could lead to more effective treatments and reduce the likelihood of side effects.
GO-ESP is comprised of five collaborative components:
HeartGO: data and specimens from a consortium of six NHLBI population study cohorts -- ARIC (Atherosclerosis Risk in Communities), CARDIA (Coronary Artery Risk Development in Young Adults), CHS (Cardiovascular Health Study), FHS (Framingham Heart Study), JHS (Jackson Heart Study), and MESA (Multi-Ethnic Study of Atherosclerosis).
LungGO: data and specimens from 50-300 individuals selected from each of the tails of the distribution from seven pulmonary disease population study cohorts, focusing on either: severity of lung disease in cystic fibrosis, time to acquisition of Pseudomonas aeruginosa in cystic fibrosis, severity of lung disease in asthma, rate of decline of lung function in chronic obstructive pulmonary disease, severity of pulmonary hypertension or severity of acute lung injury.
WHISP: data and specimens from a subset of participants selected from the tails of multiple CVD related phenotypic distributions in the Women's Health Initiative (WHI) Clinical Trial and Observational Study.
SeattleGO and BroadGO: the sequencing centers performing the exome sequencing from ~7000 genomic DNA samples derived from the above and additional NHLBI patient or family studies.
The GO-ESP consortium cohorts’ data and specimens were specifically selected for the following GO-ESP primary phenotype working groups: Anthropometry, Blood Pressure, Early-onset Myocardial Infarction (EOMI), Early-onset Stroke, Family Studies, Lipids, Lung Diseases, and Subclinical Disease/Quantitative Traits. However, the resulting datasets provide investigators with genotype-phenotype analytic opportunities for traits not only related to heart and lung disease but also associated ancillary variables that have been deposited in dbGaP, including disease endpoints, risk factors, biomarkers, and subclinical disease measures.
The data from the GO-ESP studies can be found via the links for 1) dbGaP, in the GO-ESP substudy folder for each of the contributing cohort, clinical or family study, and 2) dbSNP. Less...